Conclusion We tried to influence muscle hypertonia, defined clini

Conclusion We tried to influence muscle hypertonia, defined clinically as resistance to passive movements of extremities or their parts. The Selleckchem PD 332991 author first refers to hypertonus of central origin which we tried to suppress by subarachnoidal application of phenol, and later on by low frequency electrostimulation according to Hufschmidt’s system. Positive effects on Parkinsonian rigidity and akinesia were found as well. The adapted technique was applied with good results even on retention and incontinence of urine. For the first time, a syndrome of transient painful

cramps of peripheral genesis was differentiated as a hereditary disease without the possibility of being improved. Inhibitors,research,lifescience,medical At the same time, we developed ischemic and hyperventilation tests for chronic tetany, applying them to different conditions. The resistance in dystrophic myotony was reduced by carbamazepine or Lignocaine with unchanged spontaneous EMG activity.

As early as 1982, we differentiated a patient with neuromyotonia, whose symptoms were reduced by carbamazepine; Inhibitors,research,lifescience,medical they then completely disappeared on corticosteroids. Patients with neuromyotonia kept appearing. We differentiated a new neurological symptom of subacute contracture Inhibitors,research,lifescience,medical of fingers that disappeared very quickly on ulnar nerve neurolysis. In three unrelated patients, we differentiated slowly progressive Inhibitors,research,lifescience,medical contracture of the spine with proximal myopathy, and, until then not described, a syndrome of hereditary progressive contracture of fingers accompanied by extreme muscle percussion symptom and special repetitive EMG activity. In one patient, with spinal MR pathology the frequent, very painful paroxysmal, generalised spasms disappeared fully on corticosteroids. All these significant results were the consequence of steady application Inhibitors,research,lifescience,medical of the basic rules cited above: watch, listen and use your own common sense

and experience; ask questions and compare!
Glycogenosis II (GSD II) is an autosomal recessive lysosomal storage disorder resulting from acid alpha-glucosidase deficiency, subsequent accumulation of glycogen in tissues, impairment Linifanib (ABT-869) of autophagic processes and progressive cardiac, motor and respiratory failure. The late-onset form is characterized by wide variability in residual enzyme activity, age of onset, rate of disease progression and phenotypical spectrum. Although the pathological process mainly affects the skeletal muscle, several other tissues may be involved in the course of the disease; therefore GSD II should be regarded as a multisystem disorder in which glycogen accumulation is present in skeletal and smooth muscle, heart, brain, liver, spleen, salivary glands, kidney and blood vessels. In this review, we briefly summarize the main non-muscle targets of the pathological process in late-onset GSD II.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>